Tagged: interim review

Amnesty for Reluctant Early Stoppers in Clinical Development

In the C-Suite, virtually all biopharma companies insist on failing unsuccessful candidates faster and reallocating resources to more promising molecules. This is only rational. But the industry has a dirty little secret. This isn’t the kind of secret that stays within the confines of the C-Suite. It’s the kind that never bubbles up that high…. Read more »